SAGE - Sage Therapeutics GAAP EPS of -$2.31 misses by $0.11 revenue of $1.74M beats by $0.08M
- Sage Therapeutics press release ( NASDAQ: SAGE ): Q3 GAAP EPS of -$2.31 misses by $0.11 .
- Revenue of $1.74M (+20.8% Y/Y) beats by $0.08M .
- Cash, cash equivalents and marketable securities as of September 30, 2022 were $1.4 billion compared to $1.5 billion at June 30, 2022.
- Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025
-
Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022
-
Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD
-
Company appoints Laura Gault, M.D., Ph.D., as Chief Medical Officer, enhancing management team and advancing Sage’s position as a leader in brain health and a top-tier biopharmaceutical company
For further details see:
Sage Therapeutics GAAP EPS of -$2.31 misses by $0.11, revenue of $1.74M beats by $0.08M